Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
Retatrutide vs. Cagrilintide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
- Neither record represents a broadly FDA-approved treatment.
⇄ Different
Biggest Difference
Retatrutide is distinguished by triple agonist: it shares GIP and GLP-1 receptor activity with tirzepatide and adds glucagon-receptor activity; Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
Retatrutide is distinguished in the current record by triple agonist: it shares GIP and GLP-1 receptor activity with tirzepatide and adds glucagon-receptor activity. Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceComparable
Retatrutide: Mixed maturity. Cagrilintide: Developing human evidence.
Regulatory historyComparable
Retatrutide: Investigational. Cagrilintide: Investigational — Phase 3.
Mechanistic breadthComparable
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
Retatrutide
- Obesity
- Type 2 diabetes
- Metabolic outcomes
Cagrilintide
- Weight management
- Appetite and energy intake
- Obesity with type 2 diabetes
- Visceral and ectopic fat
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
RetatrutideInvestigational
Investigational. No FDA-approved indication, product label, consumer dose, or official storage procedure.
CagrilintideInvestigational
Investigational. No FDA-approved standalone cagrilintide product, consumer dose, reconstitution method, or official storage procedure.
Evidence depthEvidence, not a winner
RetatrutideMixed maturity
Phase 2 publications, one peer-reviewed Phase 3 diabetes report, and several sponsor-reported Phase 3 obesity toplines. Full pivotal obesity publications and long-term outcomes remain incomplete.
CagrilintidePhase 2 + Phase 3 pending
One published 706-participant Phase 2 monotherapy trial, a 105-participant thorough-QT study, sponsor-reported Phase 3 component-arm data, and two active dedicated Phase 3 RENEW trials without posted results.
Weight outcomesEvidence, not a winner
RetatrutideTopline + Phase 2
TRIUMPH-1 sponsor topline: up to −28.3% mean change at 80 weeks under the efficacy estimand. A full peer-reviewed report was not located by the cutoff.
CagrilintidePeer-reviewed Phase 2
Phase 2 reported mean reductions of 6.0% to 10.8% across studied cagrilintide arms versus 3.0% placebo at 26 weeks. A sponsor-reported Phase 3 component arm later reported 11.8% versus 2.3% at 68 weeks under an efficacy estimand.
Type 2 diabetesEvidence, not a winner
RetatrutidePeer-reviewed Phase 3
Peer-reviewed 40-week Phase 3 diabetes trial reported mean HbA1c and weight changes versus placebo.
CagrilintidePhase 3 registered
RENEW 2 is studying standalone cagrilintide in adults with overweight or obesity and type 2 diabetes; no results were posted by the cutoff.
Obstructive sleep apnoeaEvidence, not a winner
RetatrutideRegistered; results incomplete
Included in the Phase 3 TRIUMPH program, but no peer-reviewed outcome publication was located by the cutoff.
CagrilintideNo dedicated evidence
No dedicated completed controlled human obstructive-sleep-apnoea outcome study was located.
Cardiovascular outcomesEvidence, not a winner
RetatrutideOutcomes pending
Long-term cardiovascular and renal outcome trials are part of development; completed outcomes were not yet available.
CagrilintideQT study only
A 105-participant thorough-QT study found no clinically relevant QTc prolongation at the tested exposure. That narrow result is not a cardiovascular outcomes trial.
Administration and handlingEvidence, not a winner
RetatrutideTrial descriptions only
Published trial arms describe once-weekly subcutaneous administration. They are not approved dosing instructions.
CagrilintideTrial descriptions only
Published and registered studies describe once-weekly subcutaneous administration under protocol-specific escalation. These are trial descriptions, not approved dosing instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Long-term cardiovascular, renal, and rare-event safety, plus full peer-reviewed reports from the pivotal obesity trials.
- Whether the dedicated RENEW Phase 3 trials confirm long-term standalone efficacy and safety in people with and without type 2 diabetes.
Community Intelligence
Emerging patterns, clearly separated from evidence
Retatrutide
1 published experience1/10 reports toward aggregate Community IntelligenceIndividual reports available · aggregate patterns unlock at 10
Cagrilintide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.